Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Sponsor
University Hospital of Crete
Study ID
NCT00755157
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
  • Bevacizumab — DRUG
    Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression

Study Details

This trial will evaluate the efficacy and safety of metronomic docetaxel and bevacizumab combination in patients with pretreated, advanced small cell lung cancer.

Key Dates

First listed
Sep 18, 2008
Start date
Apr 30, 2008
Status verified
Oct 2015
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Docetaxel(metronomic)/Bevacizumab

Primary Outcome Measure

Objective Response Rate [ Time Frame: up to 6 months ]

Related Studies